Tag Archives: PYXS

Pyxis Oncology (PYXS), mcap=$89m, price $2.70 vs $2.76

Pre-clinical biotech at a 50% discount to its cash balance. Baby thrown out with the bathwater in biotech sell-off – down 80% since its $16/shr IPO at the end of 2021. Priced as if R&D will only destroy value – all programs are very early stage, so that is an overly exaggerated assumption. Very experienced management – led by former $PFE exec.